Hepatocellular Carcinoma — Viva Defence

Long Case Viva Defence

The scenario

A 62-year-old man with chronic hepatitis C cirrhosis (achieved SVR after DAA therapy 2 years ago) is found on six-monthly surveillance ultrasound to have a new 4.2 cm lesion in segment 6. His AFP has risen from 12 to 180 ng/mL. Multiphase MRI shows arterial phase hyperenhancement, portal venous washout, and an enhancing capsule (LI-RADS 5). There is no vascular invasion and no extrahepatic spread. The portal vein is patent. His liver function is Child-Pugh A (bilirubin 18, albumin 36, INR 1.1, no ascites, no encephalopathy). His platelet count is 95 x 10^9/L. He has small oesophageal varices on endoscopy. His ECOG is 0. He has type 2 diabetes and hypertension. [1]

Opening statement (SASPOP)

"This is Mr M, a 62-year-old man presenting with a hepatocellular carcinoma detected on six-monthly surveillance in his HCV cirrhosis (post-SVR). The multiphase MRI shows a single 4.2 cm LI-RADS 5 lesion with arterial phase hyperenhancement, washout and a capsule — diagnostic of HCC without biopsy. There is no vascular invasion or extrahepatic spread, and the portal vein is patent. His liver function is Child-Pugh A and his ECOG is 0, placing him at BCLC stage A — the curative treatment stage. However, his platelet count of 95 and small varices suggest clinically significant portal hypertension, which is a critical determinant of whether resection is safe or whether transplant or ablation is preferred. His main problems are the HCC needing curative therapy; the cirrhosis with portal hypertension; the persistence of cirrhosis despite his HCV cure; his type 2 diabetes and hypertension; his varices; and the psychosocial impact of a cancer diagnosis. My priorities are to stage him with the BCLC system, assess his portal pressure to determine the optimal curative modality, refer him to the multidisciplinary team for a resection-versus-ablation-versus-transplant decision, manage his portal hypertension, and ensure lifelong surveillance." [1]

Problem list (numbered, prioritised)

1. BCLC A hepatocellular carcinoma — the central problem; needs curative therapy.
2. Cirrhosis with clinically significant portal hypertension — complicates resection; needs portal pressure assessment and variceal prophylaxis.
3. Chronic hepatitis C (post-SVR) — cirrhosis persists; surveillance continues for life.
4. Small oesophageal varices — need primary prophylaxis.
5. Type 2 diabetes and hypertension — metabolic comorbidities to optimise before any surgery.
6. Psychosocial impact — a new cancer diagnosis on top of chronic liver disease. [1]

Integrated management plan

Pillar 1 — Confirm the staging and the BCLC allocation: "The diagnosis is confirmed by the LI-RADS 5 imaging — I do not need a biopsy in a cirrhotic liver, and biopsy carries a tumour-seeding risk [2]. His BCLC stage is A: single tumour, Child-Pugh A, ECOG 0. The key additional assessment is his portal pressure — his thrombocytopenia (platelets 95) and small varices suggest clinically significant portal hypertension (CSPH). I would confirm this with a hepatic venous pressure gradient (HVPG) if available. If the HVPG is above 10 mmHg, resection carries a high risk of post-hepatectomy liver failure, and transplant or ablation becomes the preferred curative option [2]."

Pillar 2 — Curative treatment decision: "For BCLC A disease, the curative options are resection, thermal ablation, and liver transplant. If his portal pressure is normal (HVPG under 10), surgical resection is first-line, with a five-year survival of 50 to 70 percent [2]. If he has CSPH, the options shift: he is within the Milan criteria for transplant (single lesion under 5 cm, no vascular invasion, no extrahepatic spread), and five-year post-transplant survival is around 70 percent [2][1]. Thermal ablation (RFA or MWA) is an alternative if the lesion is accessible, though for a 4.2 cm lesion ablation is less reliably complete than for sub-3 cm lesions. I would refer him urgently to the MDT for this decision."

Pillar 3 — Portal hypertension management: "I would start a non-selective beta-blocker (carvedilol 6.25 mg daily) for primary prophylaxis of variceal bleeding, given his small varices and platelet count under 150. I would repeat his endoscopy in one to two years to monitor the varices." [1]

Pillar 4 — Management of the underlying liver disease: "His HCV is cured, but the cirrhosis persists and so does his HCC risk — surveillance continues for life [1]. I would optimise his diabetes and blood pressure, assess his nutritional status (sarcopenia is common and worsens surgical outcomes), and ensure he remains under hepatology follow-up."

Pillar 5 — Lifelong surveillance: "After curative treatment, surveillance continues with six-monthly ultrasound plus AFP. The cirrhotic liver can produce new tumours, and the transplant recipient needs recurrence surveillance." [1]

Probing questions the examiner would ask

Q: Why was a biopsy not needed for the diagnosis, and when would you biopsy? [1]

A: "In a cirrhotic liver, a LI-RADS 5 lesion is diagnostic of HCC non-invasively — the imaging features of arterial phase hyperenhancement plus washout plus capsule, in a lesion of sufficient size, are pathognomonic [2]. Biopsy carries a 1 to 3 percent risk of tumour seeding along the needle track and is avoided when imaging suffices. I would biopsy in three situations: a non-cirrhotic liver where the imaging criteria are less reliable; an atypical lesion that does not meet full LI-RADS 5 criteria (LR-4 or LR-M); or when the histological diagnosis would change management — for example, distinguishing HCC from an intrahepatic cholangiocarcinoma, which has a different treatment algorithm."

Q: How do you decide between resection, ablation, and transplant for a BCLC A patient? [1]

A: "The decision hinges on three factors: the tumour characteristics, the liver function, and the portal pressure. For a single tumour under 5 cm in a Child-Pugh A patient with no clinically significant portal hypertension (HVPG under 10, no varices, normal platelets), surgical resection is first-line — five-year survival is 50 to 70 percent [2]. If the patient has clinically significant portal hypertension (HVPG above 10, clinical varices, or significant thrombocytopenia), resection is high-risk for post-hepatectomy liver failure, and the preferred options are liver transplant (within Milan criteria) or thermal ablation. For tumours under 2 to 3 cm, ablation achieves complete necrosis in over 90 percent of cases and rivals surgery. For tumours between 3 and 5 cm, resection or transplant is preferred over ablation. This patient's portal hypertension (small varices, platelets 95) makes transplant or ablation the likely preferred options unless his HVPG is reassuringly normal."

Q: What are the Milan criteria, and why do they matter? [1]

A: "The Milan criteria are the tumour burden thresholds within which liver transplant achieves an acceptable outcome: a single tumour under 5 cm, or up to 3 tumours each under 3 cm, with no macrovascular invasion and no extrahepatic spread. Within these criteria, five-year post-transplant survival is around 70 percent with a recurrence rate under 15 percent [2]. Outside these criteria, the recurrence rate is prohibitive. The Milan criteria are an ethical allocation framework — they identify the tumour burden below which transplant outcomes justify the use of a scarce donor organ. This patient is within Milan criteria (single 4.2 cm lesion, no vascular invasion, no extrahepatic spread) and is therefore a transplant candidate."

Q: What if this patient had portal vein tumour thrombus instead — how would that change the management? [1]

A: "Portal vein tumour thrombus changes everything. It upstages the patient from BCLC A to BCLC C (advanced), because vascular invasion is a defining feature of BCLC C. The treatment allocation shifts from curative therapy to systemic therapy. TACE is contraindicated because it requires a patent portal vein — embolising the hepatic artery when the portal vein is occluded risks total hepatic ischaemia. The first-line systemic therapy would be atezolizumab plus bevacizumab (after an upper GI endoscopy to screen for varices), with sorafenib or lenvatinib as alternatives [4][5][6]. The prognosis changes dramatically — from a curable early cancer to an advanced cancer with a median survival of approximately 19 months on the best systemic therapy."

Q: This patient achieved SVR for his hepatitis C 2 years ago. Why does he still have HCC risk? [1]

A: "Successful HCV eradication with direct-acting antivirals substantially reduces but does NOT eliminate the HCC risk, because the cirrhosis — the architectural distortion, the regenerative nodules, and the genomic field defect — persists after the virus is cleared [1]. The residual annual HCC risk in a cirrhotic patient post-SVR is approximately 0.5 to 1 percent, compared with 2 to 4 percent in untreated HCV cirrhosis. This is why surveillance with six-monthly ultrasound plus AFP continues for life in every patient with cirrhosis, regardless of whether the underlying cause has been treated. Stopping surveillance after SVR is one of the most common and dangerous errors in hepatology."

Q: What is the role of alpha-fetoprotein in the diagnosis and management of HCC? [1]

A: "AFP is a surveillance adjunct, not a standalone diagnostic test. It is added to six-monthly ultrasound because ultrasound alone misses small HCCs, particularly in obese or nodular livers. AFP is elevated (above 20 ng/mL) in only 60 to 70 percent of HCCs, so a normal AFP does not exclude HCC. AFP is also elevated in chronic active hepatitis without HCC, so an elevated AFP alone does not diagnose HCC — it triggers imaging. In management, the AFP trend is a useful biomarker: a rising AFP suggests progression, a falling AFP suggests treatment response. An AFP above 400 ng/mL has a specificity for HCC approaching 95 percent and is also the threshold for ramucirumab use as a second-line systemic therapy." [1]

Communication and shared decision-making

"I would explain to Mr M that his surveillance programme has done exactly what it was designed to do — detect a liver cancer at an early, curable stage. I would explain that the cancer arose from his cirrhosis, which persists despite his hepatitis C being cured, and that the cirrhosis will need lifelong monitoring. I would lay out the three curative options — resection, ablation, and transplant — and explain that the decision depends on a measurement of his portal pressure that we will arrange. I would be honest that a transplant is a major undertaking with lifelong immunosuppression, but it offers the best chance of cure because it treats both the tumour and the underlying liver disease. I would involve his family, his GP, the transplant coordinator, the dietitian, and the hepatology nurse specialist, and I would ensure he has the support to make an informed decision." [1]

Short Case Discussion — Abdominal Examination of Chronic Liver Disease with HCC

Instruction: "Examine this patient's abdomen and comment on the relevant general signs." [1]

Systematic examination routine

1. End of bed — observe for cachexia (suggesting advanced malignancy), jaundice, muscle wasting (sarcopenia of cirrhosis), spider naevi, palmar erythema, gynaecomastia, and parotid enlargement (signs of chronic liver disease). Look for a distended abdomen (ascites).
2. Hands — palmar erythema, clubbing (hypertrophic osteoarthropathy in HCC, rare), leuconychia (hypoalbuminaemia), Dupuytren contracture (alcoholic cirrhosis). Take the pulse — beta-blocker for portal hypertension may be evident.
3. Face and neck — icteric sclerae, spider naevi in the superior vena cava distribution, parotid enlargement, gynaecomastia. Cachexia of advanced malignancy.
4. Chest — spider naevi (above the nipple line), gynaecomastia, loss of axillary hair.
5. Abdomen — inspect — distension (ascites), caput medusae (recanalised umbilical vein), surgical scars, cachexia.
6. Abdomen — palpate — start away from the painful area. Feel for hepatomegaly (a hard, irregular liver edge suggests HCC or macronodular cirrhosis), a palpable gallbladder (Courvoisier sign, but this is for biliary obstruction, not HCC), splenomegaly (portal hypertension), and a ballotable liver edge. Assess for ascites (shifting dullness, fluid thrill).
7. Abdomen — percuss — the liver span, splenic dullness, and shifting dullness for ascites.
8. Abdomen — auscultate — a bruit over the liver (rare; can be heard in HCC with arteriovenous shunting).
9. Complete the examination — examine for peripheral oedema, test for asterixis (hepatic encephalopathy), and check the mental state. [1]

Key physical signs the patient demonstrates (for this case)

• Cachexia and muscle wasting (sarcopenia of cirrhosis and possible malignancy)
• Spider naevi and palmar erythema (chronic liver disease)
• A hard, irregular liver edge palpable below the costal margin (hepatomegaly from HCC on cirrhosis)
• Splenomegaly (portal hypertension from cirrhosis)
• Mild ascites (if decompensated) [1]

Presentation template

"I examined Mr M, a 62-year-old man who appears cachectic at the end of the bed, with muscle wasting of the temporalis and thenar eminences suggesting sarcopenia. The hands show palmar erythema and no clubbing. The face shows icteric sclerae and several spider naevi. The chest shows spider naevi in the superior vena cava distribution and mild gynaecomastia. The abdomen reveals a hard, irregular liver edge palpable 4 cm below the costal margin, and a palpable spleen tip. There is no ascites. These findings — the stigmata of chronic liver disease with a hard, irregular hepatomegaly — are consistent with a hepatocellular carcinoma arising on the background of cirrhosis. I would like to check the alpha-fetoprotein, arrange a multiphase CT or MRI of the liver reported with LI-RADS, and stage the patient with the BCLC system to guide treatment." [1]

Discussion questions

Q: How do you stage HCC, and why does the staging system matter? [1]

A: "I stage HCC using the Barcelona Clinic Liver Cancer (BCLC) system, which integrates three dimensions: tumour burden, liver function (Child-Pugh score), and performance status (ECOG). It matters because each stage links to a specific first-line treatment — BCLC 0 and A are curative (resection, ablation, transplant), B is TACE, C is systemic therapy, and D is best supportive care. The BCLC system is the global standard and is the framework around which all HCC management decisions are organised [2][1]."

Q: What is LI-RADS, and how does it change the diagnostic approach? [1]

A: "LI-RADS (Liver Imaging Reporting and Data System) is a standardised algorithm for categorising liver observations on multiphase CT or MRI in patients at risk for HCC. It ranges from LR-1 (definitely benign) to LR-5 (definitely HCC). The key principle is that in a cirrhotic liver, a LI-RADS 5 lesion is diagnostic of HCC without biopsy — the imaging features (arterial phase hyperenhancement plus washout plus capsule, in a lesion of sufficient size) are pathognomonic. LI-RADS also defines LR-M (malignant, not specific for HCC — needs biopsy) and LR-TIV (tumour in vein — vascular invasion). LI-RADS has standardised the non-invasive diagnosis of HCC and is endorsed by the AASLD and ACR [2]."

Q: What is the current first-line systemic therapy for advanced HCC, and what is the critical pre-treatment requirement? [1]

A: "The current first-line therapy for BCLC C HCC in a Child-Pugh A patient is atezolizumab (a PD-L1 inhibitor) plus bevacizumab (a VEGF inhibitor), based on the IMbrave150 trial which showed a median OS of 19.2 months versus 13.4 months with sorafenib [4]. The critical pre-treatment requirement is an upper GI endoscopy to screen for and treat varices — bevacizumab can precipitate catastrophic bleeding from untreated varices. This is non-negotiable and is a high-yield safety point. If immunotherapy is contraindicated, sorafenib or lenvatinib are the single-agent TKI alternatives [5][6]."

Q: Why can HCC occur in a non-cirrhotic patient with hepatitis B? [1]

A: "Hepatitis B is unique among HCC risk factors because it causes HCC through direct viral oncogenesis — HBV DNA integrates into the host genome, activating oncogenic pathways (particularly via the HBx protein), independent of the cirrhosis pathway. This is why HBV carriers are offered HCC surveillance even without cirrhosis (Asian men over 40, Asian women over 50, African-descent patients over 20, and those with a family history). It is also why the HBV vaccine is the only vaccine that prevents a human cancer — it prevents the viral infection that drives the oncogenesis [1]."

Q: What surveillance does a cirrhotic patient need, and for how long? [1]

A: "Every patient with cirrhosis (Child-Pugh A and B, and those who are transplant candidates) needs six-monthly liver ultrasound plus serum alpha-fetoprotein, for life. The surveillance continues regardless of whether the underlying cause has been treated — the cirrhosis persists after HCV eradication, alcohol abstinence, or metabolic optimisation, and so does the HCC risk. The Singal 2014 meta-analysis confirmed that this surveillance improves early detection, curative treatment rates, and overall survival [3]. The six-monthly interval is based on HCC tumour doubling times."